Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00533091 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT00533091 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 51 participants.
The verdict
NCT00533091, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the safety and tolerability of multiple IV doses of MEDI-545 in adult patients with myositis.
Interventions
- OTHER Placebo
- BIOLOGICAL MEDI-545
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00533091
The ClinicalTrials.gov registry entry for NCT00533091 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00533091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00533091 about?
NCT00533091 is a clinical study titled "A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis". The primary objective of the study is to evaluate the safety and tolerability of multiple IV doses of MEDI-545 in adult patients with myositis.
What is the current status of trial NCT00533091?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2008-04. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00533091?
The interventions under investigation include: Placebo (OTHER), MEDI-545 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00533091?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.